Merck KGaA, SpringWorks
Hosted on MSN1mon
Merck Ends Development of Two Experimental Cancer DrugsMerck MRK decided to discontinue two clinical development programs, namely KeyVibe and KEYFORM, which are evaluating its investigational cancer drugs vibostolimab and favezelimab, respectively.
Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on strong efficacy shown in previous studies, the drugmaker said on Thursday.
Merck & Co has followed the lead of other big pharma groups like Pfizer and GlaxoSmithKline by hiving off its mature and off-patent drugs into a new company. The decision will take some 90 ...
the best-selling drug in the world, to decline in the coming years? And can they trust Merck’s guidance on that decline? The problems with Gardasil relate entirely to sales of the vaccine in ...
Merck CEO Rob Davis told CNBC's Jim Cramer that there's more to the pharmaceutical giant than its lucrative cancer drug, Keytruda, and he described other ventures in its portfolio. "Keytruda has ...
Merck & Co has extended its range of cancer medicines in the US after claiming FDA approval for Welireg – a drug it acquired as part of its $2.2 billion takeover of Peloton Therapeutics in 2019 ...
Jan 24 (Reuters) - Merck (MRK.N), opens new tab and Japan-based Eisai (4523.T), opens new tab said on Friday a combination of their therapies failed to extend the lives of patients with a type of ...
Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension (PAH) drug, Winrevair (sotatercept), for a more advanced version of ...
Merck reported third-quarter revenue and adjusted earnings that topped expectations. The company saw strong sales from its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback